Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial (2019)
- Autores:
- Autor USP: NAHAS, WILLIAM CARLOS - FM
- Unidade: FM
- DOI: 10.1016/S1470-2045(18)30860-X
- Assuntos: NEOPLASIAS PROSTÁTICAS; METÁSTASE NEOPLÁSICA; NEOPLASIAS ÓSSEAS; ESTEROIDES; ANDRÓGENOS
- Agências de fomento:
- Idioma: Inglês
- Imprenta:
- Fonte:
- Título do periódico: Lancet oncology
- ISSN: 1470-2045
- Volume/Número/Paginação/Ano: v. 20, n. 3, p. 408-419, 2019
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
SMITH, Matthew et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet oncology, v. 20, n. 3, p. 408-419, 2019Tradução . . Disponível em: https://doi.org/10.1016/S1470-2045(18)30860-X. Acesso em: 30 set. 2024. -
APA
Smith, M., Parker, C., Saad, F., Miller, K., Tombal, B., Ng, Q. S., et al. (2019). Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet oncology, 20( 3), 408-419. doi:10.1016/S1470-2045(18)30860-X -
NLM
Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, Boegemann M, Matveev V, Piulats JM, Zucca LE, Nahas WC. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial [Internet]. Lancet oncology. 2019 ; 20( 3): 408-419.[citado 2024 set. 30 ] Available from: https://doi.org/10.1016/S1470-2045(18)30860-X -
Vancouver
Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, Boegemann M, Matveev V, Piulats JM, Zucca LE, Nahas WC. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial [Internet]. Lancet oncology. 2019 ; 20( 3): 408-419.[citado 2024 set. 30 ] Available from: https://doi.org/10.1016/S1470-2045(18)30860-X - Transplante renal com doador "cadaver": relacao de aspectos do doador, do receptor e do ato cirurgico com a evolucao do doente
- A rare case of tumor-to-tumor metastasis: prostate cancer to chromophobe renal cell carcinoma
- Current concepts in multiparametric magnetic resonance imaging for active surveillance of prostate cancer. [Editorial]
- Subcostal mini incision: a good option for donor nephrectomy
- Home blood pressure (BP) monitoring in kidney transplant recipients is more adequate to monitor BP than office BP
- Caliceal-cutaneous Fistula After Kidney Transplantation
- Prognostic factors of renal cell carcinoma with venous tumor extension
- Renal cell carcinoma in the native kidney in dialysis and kidney transplant recipients. comparison of pathological features and ACKD influence: a prospective analysis
- Case 297. [Editorial]: Mucinous adenocarcinoma of the prostate.
- Histologic Inflammatory Changes on the Prostatic Gland Due to Immunosuppression for Kidney Transplantation
Informações sobre o DOI: 10.1016/S1470-2045(18)30860-X (Fonte: oaDOI API)
Como citar
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
